People with ANCA-associated vasculitis (AAV) are at a higher risk of developing certain types of cancer, particularly bladder, blood, kidney,…
Articles by Patricia Inacio, PhD
Adding Tavneos (avacopan) to standard treatment is as safe and effective in older people with ANCA-associated vasculitis (AAV)…
A higher risk of death among AAV patients with interstitial lung disease (ILD) is significantly associated with older age, episodes…
Long-term treatment with Nucala (mepolizumab) reduces disease activity and helps to prevent progressive organ damage in people with eosinophilic granulomatosis…
Plasma exchange added to standard immunosuppressive treatments helps improve early kidney function in people with ANCA-associated vasculitis (AAV) who…
High blood levels of the syndecan-1 protein, known to promote the survival of antibody-producing B cells, may help identify…
Using data from the largest ANCA-associated vasculitis (AAV) patient database compiled to date, researchers identified five new subgroups that…
Treatment with the asthma medication montelukast may trigger eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated…
Melodia Therapeutics has acquired the exclusive rights to develop, manufacture, and commercialize MDI-0151, a candidate therapy for hard-to-treat…
Sinonasal manifestations — those encompassing the nose and the paranasal sinuses, or the air-filled cavities around the nose — in…